SWM
BIB icon

SeaCrest Wealth Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

SeaCrest Wealth Management’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-500
Closed -$35K – 2149
2018
Q3 		$35K Buy
500
+130
+35% +$8.5K 0.01% 1142
2018
Q2 		$21K Hold
370
– – ﹤0.01% 1333
2018
Q1 		$20K Hold
370
– – ﹤0.01% 1322
2017
Q4 		$21K Buy
+370
New +$20.9K ﹤0.01% 1315

Other funds holding BIB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $474M AUM 95.11% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Tower Research Capital (TRC)
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BRC
Bell Rock Capital Rehoboth Beach, Delaware $81M AUM 9.85% 1-Year Est. Return
BA
BKS Advisors Southfield, Michigan $249M AUM 14.37% 1-Year Est. Return
SBIA
Sheaff Brock Investment Advisors Indianapolis, Indiana $1.09B AUM 14.4% 1-Year Est. Return
Capital Investment Advisors
Capital Investment Advisors Atlanta, Georgia $7.59B AUM 23.38% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return

SeaCrest Wealth Management's BIB Position: Q4 2018 in Review

SeaCrest Wealth Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q4 2018, closing a stake of 500 shares — an estimated $35K sold.

SeaCrest Wealth Management first reported a position in BIB in Q4 2017 and held it in 4 quarters. The position peaked at $35K in Q3 2018. 27 funds tracked by Wall St. Rank hold BIB as of Q4 2018.

  • SeaCrest Wealth Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q4 2018 after selling out during the quarter.
  • SeaCrest Wealth Management sold 500 ProShares Ultra NASDAQ Biotechnology shares in Q4 2018, an estimated $35K.
  • SeaCrest Wealth Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2017 and held it in 4 quarters.
  • SeaCrest Wealth Management's ProShares Ultra NASDAQ Biotechnology position peaked at $35K in Q3 2018.
  • 27 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2018.

Based on SeaCrest Wealth Management's 13F filing for Q4 2018, filed 13 Feb 2019.